The effect of lentivirus-mediated expression of tumor necrosis factor related apoptosis-inducing ligand and shRNA against Bcl-2 on the growth of lymphoma cells

References

• Baris D, Zahm SH. Epidemiology of lymphomas. Curr Opin Oncol 2000;12:383–394.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 2010;51: 983–994.
   PubMed Web of Science ®Google Scholar
• Alousi AM, Uberti J, Ratanatharathorn V. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma 2010;51:376–389.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Winter JN, Gordon LI, . Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. Leuk Lymphoma 2010;51:1163–1177.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Fisher RI. Novel therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol 2011;29:1876–1884.
   PubMed Web of Science ®Google Scholar
• Buttgereit P, Schakowski F, Marten A, . Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells. Cancer Gene Ther 2001;8:430–439.
   PubMed Web of Science ®Google Scholar
• Ebert O, Wilbert D, Buttgereit P, . Effects of recombinant adenovirus-mediated expression of IL-2 and IL-12 in human B lymphoma cells on co-cultured PBMC. Genet Vaccines Ther 2004;2:15.
   Google Scholar
• Misumi M, Suzuki T, Moriuchi S, . In vitro thymidine kinase/ganciclovir-based suicide gene therapy using replication defective herpes simplex virus-1 against leukemic B-cell malignancies (MCL, HCL, B-CLL). Leuk Res 2003;27:695–699.
   PubMed Web of Science ®Google Scholar
• Buttgereit P, Schmidt-Wolf IG. Gene therapy of lymphoma. J Hematother Stem Cell Res 2002;11:457–467.
   PubMedGoogle Scholar
• Godfrey A, Anderson J, Papanastasiou A, . Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 2005;105:2510–2518.
   PubMed Web of Science ®Google Scholar
• Buttgereit P, Weineck S, Ropke G, . Efficient gene transfer into lymphoma cells using adenoviral vectors combined with lipofection. Cancer Gene Ther 2000;7:1145–1155.
   PubMed Web of Science ®Google Scholar
• Zhu J, Chen Y. [Research of lentiviral vector mediated growth factor gene-modified bone marrow mesenchymal stem cells]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2010;24:972–976.
   PubMedGoogle Scholar
• Zhang X, Zhao L, Hang Z, . Evaluation of HSV-1 and adenovirus vector-mediated infection, replication and cytotoxicity in lymphoma cell lines. Oncol Rep 2011;26:637–644.
   PubMed Web of Science ®Google Scholar
• Alain T, Thirukkumaran C, Morris DG, . Lymphomas and oncolytic virus therapy. Clin Lymphoma 2003;4:104–111.
   PubMedGoogle Scholar
• Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440–442.
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, O'Connor OA. Targeting survival pathways in lymphoma. Adv Exp Med Biol 2010;687:79–96.
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Moldoveanu T, Llambi F, . The BCL-2 family reunion. Mol Cell 2010;37:299–310.
   PubMed Web of Science ®Google Scholar
• Welbourne T, Nissim I. Regulation of mitochondrial glutamine/glutamate metabolism by glutamate transport:studies with (15)N. Am J Physiol Cell Physiol 2001;280:C1151–C1159.
   PubMed Web of Science ®Google Scholar
• Thorburn A. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway signaling. J Thorac Oncol 2007;2:461–465.
   Google Scholar
• Wajant H. CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. Cancer Treat Res 2006;130:141–165.
   PubMedGoogle Scholar
• Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782–798.
   PubMed Web of Science ®Google Scholar
• Falschlehner C, Schaefer U, Walczak H. Following TRAIL's path in the immune system. Immunology 2009;127:145–154.
   PubMed Web of Science ®Google Scholar
• Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010;29:4752–4765.
   PubMed Web of Science ®Google Scholar
• Begue B, Wajant H, Bambou JC, . Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology 2006;130:1962–1974.
   PubMed Web of Science ®Google Scholar
• Wiley SR, Schooley K, Smolak PJ, . Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673–682.
   PubMed Web of Science ®Google Scholar
• Griffith TS, Stokes B, Kucaba TA, . TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther 2009;9:9–19.
   PubMed Web of Science ®Google Scholar
• Shah K, Tung CH, Yang K, . Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Res 2004;64:3236–3242.
   PubMed Web of Science ®Google Scholar
• Kock N, Kasmieh R, Weissleder R, . Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia 2007;9:435–442.
   PubMedGoogle Scholar
• Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 2010;14:1091–1108.
   PubMed Web of Science ®Google Scholar
• Secchiero P, Vaccarezza M, Gonelli A, . TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies. Curr Pharm Des 2004;10:3673–3681.
   PubMed Web of Science ®Google Scholar
• Lois C, Hong EJ, Pease S, . Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002;295:868–872.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhang CL, Zeng BF, . Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing. Biochem Biophys Res Commun 2009;390:642–647.
   PubMed Web of Science ®Google Scholar
• Sastry L, Johnson T, Hobson MJ, . Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther 2002;9:1155–1162.
   PubMed Web of Science ®Google Scholar
• Kuhn DM, Balkis M, Chandra J, . Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J Clin Microbiol 2003;41:506–508.
   PubMed Web of Science ®Google Scholar
• Seol JY, Park KH, Hwang CI, . Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther 2003;10:540–548.
   PubMed Web of Science ®Google Scholar
• Huang X, Lin T, Gu J, . Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene. Int J Oncol 2003;22:1241–1245.
   PubMed Web of Science ®Google Scholar
• Lu G, Punj V, Chaudhary PM. Proteasome inhibitor bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Cancer Biol Ther 2008;7:603–608.
   PubMed Web of Science ®Google Scholar
• Liang XS, Caporaso N, McMaster ML, . Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br J Haematol 2009;146:418–423.
   PubMed Web of Science ®Google Scholar
• Cheng J, Hylander BL, Baer MR, . Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol Cancer Ther 2006;5:1844–1853.
   PubMed Web of Science ®Google Scholar
• Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009;15:1126–1132.
   PubMed Web of Science ®Google Scholar
• Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002;21:2283–2294.
   PubMed Web of Science ®Google Scholar
• Anastasov N, Klier M, Koch I, . Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer. J Hematop 2009;2:9–19.
   PubMedGoogle Scholar
• Abbas-Terki T, Blanco-Bose W, Deglon N, . Lentiviral-mediated RNA interference. Hum Gene Ther 2002;13:2197–2201.
   PubMed Web of Science ®Google Scholar
• Keim C, Grinstein V, Basu U. Recombinant retroviral production and infection of B cells. J Vis Exp 2011;(48). pii: 2371.
   PubMedGoogle Scholar